Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 18/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2245193 | 0.87 | MMP2 (0.43) | TP53MAPTMMP2MMP8MMP12 | |
| SCHEMBL2247913 | 0.85 | MMP2 (0.39) | MMP2MMP8MMP12ADAMTS5 | |
| SCHEMBL2248296 | 0.84 | MMP2 (0.40) | PPARAMMP2MMP8MMP12ADAMTS5 | |
| SCHEMBL2251479 | 0.82 | DRD2 (0.39) | MAPTPPARAMMP2MMP8MMP12 | |
| SCHEMBL2245312 | 0.82 | HSD17B1 (0.43) | MMP2MMP8MMP12ADAMTS5 | |
| SCHEMBL2248091 | 0.82 | HSD17B2 (0.41) | PPARAMMP2MMP8MMP12ADAMTS5 | |
| SCHEMBL2247162 | 0.82 | MMP2 (0.37) | MMP2MMP8MMP12ADAMTS5 | |
| SCHEMBL2247786 | 0.82 | HSD17B2 (0.46) | MMP2MMP8MMP12ADAMTS5 | |
| SCHEMBL2244705 | 0.81 | RXRA (0.42) | MMP2MMP8MMP12ADAMTS5 | |
| SCHEMBL2245867 | 0.81 | MMP2 (0.40) | MAPTMMP2MMP8MMP12ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | claimed |
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | PPARD 3286/4885TP53 4136/4885MAPT 1544/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | PPARD 3286/4885TP53 4136/4885MAPT 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.